Clinical Report: Stockholm3 Detected More Significant Prostate Cancers Than PSA
Overview
The Stockholm3 screening test identified more clinically significant prostate cancers than traditional prostate-specific antigen (PSA) testing within a 2-year follow-up period. This secondary analysis of the STHLM3-MRI trial involved 12,670 men and demonstrated that Stockholm3 had a sensitivity of 90% compared to 74% for PSA.
Background
Prostate cancer screening is crucial for early detection and treatment, particularly for clinically significant cancers. Traditional PSA testing has limitations, including lower sensitivity and higher false-negative rates. The introduction of the Stockholm3 test, which combines PSA with additional biomarkers and clinical factors, aims to improve detection rates.
Data Highlights
| Screening Method | Sensitivity | False-Negative Rate | Specificity | False-Positive Rate |
|---|---|---|---|---|
| Stockholm3 | 90% | 10% | 89% | 11% |
| PSA | 74% | 26% | 90% | 10% |
Key Findings
- Stockholm3 detected 400 clinically significant prostate cancers, while PSA detected 327.
- Stockholm3 had a sensitivity of 90% compared to 74% for PSA.
- Stockholm3 missed 43 clinically significant cancers, whereas PSA missed 116.
- Specificity was similar between both tests, at 89% for Stockholm3 and 90% for PSA.
- Per 1,000 men screened, Stockholm3 detected approximately 32 significant cancers compared to 26 by PSA.
- Decision curve analysis indicated greater clinical net benefit for Stockholm3 across biopsy decision thresholds.
Clinical Implications
The findings suggest that integrating the Stockholm3 test into prostate cancer screening protocols may enhance the detection of clinically significant cancers while maintaining similar specificity to PSA testing. This could lead to more informed decision-making regarding biopsy referrals.
Conclusion
The Stockholm3 test demonstrates superior sensitivity in detecting clinically significant prostate cancers compared to traditional PSA testing.
Related Resources & Content
- the pathologist, The Pathologist, 2026 -- Stockholm3 Test Cuts MRIs in Prostate Screening
- The ASCO Post, The ASCO Post, 2014 -- PSA—It Just Keeps Getting Better, So Why Should It Stand Alone?
- The ASCO Post, The ASCO Post, 2026 -- Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
- Final Recommendation Statement: Screening for Prostate Cancer | United States Preventive Services Taskforce
- Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial - ScienceDirect
- Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial - PubMed
- The ASCO Post — Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
- Final Recommendation Statement: Screening for Prostate Cancer | United States Preventive Services Taskforce
- Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial - ScienceDirect
- Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
